A microRNA meta-signature for pancreatic ductal adenocarcinoma. (April 2014)

• Record Type: Journal Article
• Authors: Frampton, Adam E; Giovannetti, Elisa; Jamieson, Nigel B; Krell, Jonathan; Gall, Tamara MH; Stebbing, Justin; Jiao, Long R; Castellano, Leandro
• Is Part Of: Expert review of molecular diagnostics. Volume 14:Number 3(2014)
• Page Start: 267
• Page End: 271
• Publication Date: 2014-04
• Subjects: Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1586/14737159.2014.893192
• Languages: English
• ISSNs: 1473-7159

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>Evaluation of:</bold> Ma MZ, Kong X, Weng MZ <italic>et al</italic>. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. <italic>J. Exp. Clin. Cancer Res.</italic> 32(1), 71 (2013).</p> <p>Due to its aggressive and late presentation, there is an urgent need for novel and reliable biomarkers for the diagnosis and prognostication of pancreatic ductal adenocarcinoma (PDAC). MiRNAs have been extensively profiled in PDAC tissues, biopsies, blood samples and other biofluids and their expression levels compared to normal and chronic pancreatitis (CP) specimens in order to identify the most relevant candidates. Consolidation of these activities has not been attempted until now. The evaluated meta-review by Ma <italic>et al.</italic> helps to define the use of miRNAs as biomarkers for detecting this tumor-type and predicting survival outcomes in PDAC. Based on frequency and consistency between microarray studies, they identified a miRNA meta-signature for recognising PDAC: upregulation of miR-21, 23a, 31, 100, 143, 155, and 221; with downregulation of miR-148a, 217 and 375. Furthermore, they validated high miR-21, high miR-31 and low miR-375 tumoural expression as independently prognostic for poor overall-survival (OS; n = 70).</p> </abstract>